As of June 30, 2026, there were 20,000,000 shares of common stock authorized, 12,520,490 shares issued, and 12,336,086 shares outstanding. The par value for the common stock is $0.001 per share.

The Company’s stock-based compensation generally includes stock options, restricted stock units (“RSUs”), performance-vesting restricted stock units (“PRSUs”), and purchases under the Company’s 2019 Employee Stock Purchase Plan (the “ESPP”). Stock-based compensation expense related to RSUs is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period. The stock-based compensation expense related to PRSUs is estimated at the grant date based on the expectation that performance goals will be achieved at the stated target level. The amount of compensation cost recognized depends on the relative satisfaction of the performance condition based on performance to date.

The Company’s 2019 Stock Incentive Plan became effective on April 11, 2019. The 2019 Stock Incentive Plan, as amended and restated, allows the Company’s employees and directors to participate in the Company’s future performance through grants of stock-based awards of stock options and RSUs at the discretion of the board of directors. The number of shares authorized for issuance under the 2019 Stock Incentive Plan as of June 30, 2026 was 3,487,182. Options to acquire common stock granted under the 2019 Stock Incentive Plan have ten-year terms. As of June 30, 2026, 52,949 shares of common stock remained available for issuance (taking into account all stock option exercises and other equity award settlements through June 30, 2026).

The number of shares authorized for issuance under the ESPP as of June 30, 2026 was 300,000 shares. As of June 30, 2026, there are no shares of common stock available for issuance under the ESPP (taking into account all share purchases through June 30, 2026).

There are 1,027,489 shares of common stock authorized and reserved for issuance under the Inducement Plan. As of June 30, 2026, 80,142 shares of common stock remained available for issuance under the Inducement Plan (taking into account all option exercises and other equity award settlements through June 30, 2026).


	Stock Option Activity			Weighted Average Remaining Contractual Term (In years)	Aggregate Intrinsic Value (In thousands)
	Options (In thousands)	Weighted Average Exercise Price
Balance outstanding at December 31, 2025	178	$	184.30	5.92	$	—


Cancelled or expired	(6)	321.40
Balance outstanding at June 30, 2026	172	179.83		5.59	—
Options vested and expected to vest	99	302.36		3.91	—
Options exercisable at June 30, 2026	79	$	373.58	2.60	$	—

The total fair value of stock options exercised during the six months ended June 30, 2026 and 2025 was immaterial. As of June 30, 2026, there was $0.3 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements. That cost is expected to be recognized over a weighted average period of approximately 1.2 years.

The following table is a summary of the Company’s RSU and PRSU activity and weighted average grant date fair value for the six months ended June 30, 2026:


	Number of Shares	Weighted Average Grant Date Fair Value		Aggregate Fair Value

	(In thousands)	(Per share)		(In thousands)
Balance outstanding at December 31, 2025	783	$	15.45	$	3,028
Awarded	44	3.76
Vested	(204)	18.32
Forfeited	(24)	21.50
Non-vested and outstanding at June 30, 2026	599	13.38		1,137
Expected to vest	523	$	13.69	$	994

RSUs granted to employees generally vest over a one to four-year period, or upon achievement of certain performance conditions. As of June 30, 2026, total unrecognized compensation cost, adjusted for estimated forfeitures, related to nonvested RSUs and PRSUs was $3.2 million and the weighted-average remaining vesting period was 0.9 years.

PRSUs granted are generally subject to both a service-based vesting condition and a performance-based vesting condition. PRSUs will vest upon the achievement of specified performance targets and subject to continued service through the applicable vesting dates. The associated compensation cost is recognized over the requisite service period when it is probable that the performance condition will be satisfied. There were no PRSUs granted during the three and six months ended June 30, 2026 and 2025, respectively.

Total stock-based compensation costs included in the condensed consolidated statements of operations for the three and six months ended June 30, 2026 and 2025 are as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025

	(In thousands)				(In thousands)
Cost of revenue	$	55	$	203	$	136	$	389
Sales and marketing	577		1,059		1,084		2,437
General and administrative	1,285		1,755		2,438		3,528
Product development	420		1,243		941		2,615
Total	$	2,337	$	4,260	$	4,599	$	8,969